Genprex to Present at the RHK Capital 4th Annual Disruptive Growth Conference
August 21, 2019
AUSTIN, Texas & CAMBRIDGE, Mass.— (August 21, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that its Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4thAnnual Disruptive Growth Conference hosted by ReedSmith in New York City on September 4, 2019.
Genprex will present at the 4thAnnual Disruptive Growth Conference as follows:
Date: Wednesday, September 4, 2019
Time: 5:00-5:15 p.m. EDT
Venue: ReedSmith Offices, 599 Lexington Avenue, 22ndFloor, New York City
Room: Presentation Room A/B
The 2019 Disruptive Growth Conference will offer the exclusive opportunity to discover growth companies with disruptive technologies and business models covering the following sectors: communications, consumer, energy/alternative energy, healthcare, industrial, life sciences, natural resources and technology.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and other serious diseases who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases. The company’s lead product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC), uses the company’s unique, proprietary platform which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. In January 2020, the FDA granted Fast Track Designation for Oncoprex in combination with AstraZeneca’s Tagrisso® for the treatment of NSCLC. For more information, please visit the company’s website at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effects of Oncoprex, or Oncoprex in combination with targeted therapies or immunotherapies, on cancer. Risks and uncertainties associated with Genprex and its lead product candidate Oncoprex are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
(877) 774-GNPX (4679)